BioAtla Investor Presentation Deck

Potential market opportunity in SCCHN ● >400K ~50% people living with head and bicatla neck cancer (U.S.)¹1 with locally advanced disease develop recurrent or refractory disease² ~66K 2L+ newly diagnosed cases / year (U.S.)¹ limited effective options post IL³ Available Treatment 1L: Pembro, cetuximab, platinum 36% ORR4 2L+: ICIS 13% -16% ORR4 Target population: ~12K ROR2+ addressable 2L+ patients/year in the U.S.1, based on a ROR2 positivity rate of ~60% Internal success threshold: 2L+ ORR of ~15% (approvability bar based on precedent); 15% + (commercially relevant) following BA3011 monotherapy ¹Clarivate, Disease Landscape and Forecast: SCCHN (2022). www.cancer.net; 2Argiris A, et al. (2017) Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Front. Oncol. 7:72; ³Future Oncology, Jan. 2019. Vol. 15, No. 8; 4Ketruda USPI accessed June 2022; Opdivo USPI access June 2022. SCCHN, squamous cell carcinoma of the head and neck; 1L, first line; 2L, second line; 2L+, second line or greater; ICIS - Immune checkpoint inhibitors. BioAtla| Overview 29

View entire presentation